Skip to main content

CORRECTION article

Front. Reprod. Health, 05 December 2023
Sec. HIV and STIs
Volume 5 - 2023 | https://doi.org/10.3389/frph.2023.1341771
This article is part of the Research Topic Multipurpose Prevention Technologies: Call for Innovative Strategies to Address Critical Priorities and Gaps View all 13 articles

Corrigendum: How might we motivate uptake of the Dual Prevention Pill? Findings from human-centered design research with potential end users, male partners, and healthcare providers

This article is a correction to:

  1. How might we motivate uptake of the Dual Prevention Pill? Findings from human-centered design research with potential end users, male partners, and healthcare providers

    1. Read original article
\r\nWawira NyagahWawira Nyagah1Kate Segal Kate Segal1*Jess FelthamJess Feltham2Alex AshAlex Ash2Jocelyn Major,&#x;Jocelyn Major2,†Moowa Masani\r\nMoowa Masani3
  • 1AVAC, Product Introduction and Access, New York, NY, United States
  • 2M&C Saatchi World Services, London, United Kingdom
  • 3REACH Consumer Insights, Cape Town, South Africa

A Corrigendum on

How might we motivate uptake of the Dual Prevention Pill? Findings from human-centered design research with potential end users, male partners, and healthcare providers

By Nyagah W, Segal K, Feltham J, Ash A, Major J, Masani M, (2023). Front. Reprod. Health 5:1254953. doi: 10.3389/frph.2023.1254953

Text correction

In the published article, one of our contributors was omitted from the Acknowledgements section of the article. A correction has been made to Acknowledgements. This section previously stated:

“The authors are grateful for the generous support from the Children's Investment Fund Foundation (CIFF) for this research. The contents of this paper are the sole responsibility of the authors and do not necessarily reflect the views of CIFF. The authors would like to thank colleagues at AVAC and M&C Saatchi World Services for their guidance on the research and review of the manuscript, and members of the DPP Advisory Board and DPP Civil Society Advisory Group for providing feedback on the research at multiple stages throughout the process. Finally, the research would not have been possible without the critical contributions of field research teams and research participants in Kenya, South Africa, and Zimbabwe.”

The corrected section appears below:

“The authors are grateful for the generous support from the Children's Investment Fund Foundation (CIFF) for this research. The contents of this paper are the sole responsibility of the authors and do not necessarily reflect the views of CIFF. The authors would like to thank colleagues at AVAC and M&C Saatchi World Services for their guidance on the research and review of the manuscript. Humanly supported the design of HCD research tools, trained field research teams, analyzed outputs of the HCD research, and helped develop the user journeys and personas. Members of the DPP Advisory Board and DPP Civil Society Advisory Group provided feedback on the research at multiple stages throughout the process. Finally, the research would not have been possible without the critical contributions of field research teams and research participants in Kenya, South Africa, and Zimbabwe.”

The authors apologize for this error and affirm that this does not change the scientific conclusions of the article in any way. The original article has been updated.

Publisher's note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Keywords: pre-exposure prophylaxis, oral contraception, HIV prevention, family planning, multi-purpose prevention technologies, end users, human-centered design, demand generation

Citation: Nyagah W, Segal K, Feltham J, Ash A, Major J and Masani M (2023) Corrigendum: How might we motivate uptake of the Dual Prevention Pill? Findings from human-centered design research with potential end users, male partners, and healthcare providers. Front. Reprod. Health 5:1341771. doi: 10.3389/frph.2023.1341771

Received: 20 November 2023; Accepted: 23 November 2023;
Published: 5 December 2023.

Approved by: Frontiers In Reproductive Health, Frontiers Media SA, Switzerland

*Correspondence: Kate Segal kate@avac.org

†PRESENT ADDRESSJocelyn Major,McCann London, London, United Kingdom

© 2023 Nyagah, Segal, Feltham, Ash, Major and Masani. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.